ThermoGenesis Corp Signs Strategic Supply Agreement with Orthohealing Center Management to Provide it's PXP® Point-of-Care System to Orthohealing Method™ Physician Members
Haihong Zhu, ThermoGenesis' President, stated, "We are pleased to support OCM's rapidly expanding base of physician members who provide regenerative treatments for orthopaedic, sports medicine and pain management.
RANCHO CORDOVA, Calif., Feb. 1, 2019 /PRNewswire/ -- ThermoGenesis Corp., a private corporation owned by Cesca Therapeutics (Nasdaq: KOOL), has entered into a Supply Agreement with Orthohealing Center Management (OCM) that will allow the OCM network of physicians to utilize the ThermoGenesis PXP system to prepare a precise cell concentrate from autologous bone marrow in their office laboratories in order to provide the benefits of their Orthohealing Method to their patients.
Haihong Zhu, ThermoGenesis' President, stated, "We are pleased to support OCM's rapidly expanding base of physician members who provide regenerative treatments for orthopaedic, sports medicine and pain management. We believe this agreement benefits both parties as our market penetration of the PXP system grows and Orthohealing Method members obtain cost-effective, 'closed system' sterile cell processing with our cutting-edge technology."
The PXP system is laboratory equipment that automates the harvest of a precise volume of cell concentrate from bone marrow aspirate in a sterile, "functionally closed" process at the point-of-care. PXP can generate a concentration of bone marrow mononuclear cells, CD34+ progenitor cells and platelets in less than 20 minutes while depleting > 98% of contaminating RBCs and excess plasma for use in OCM's Orthohealing Method. Processing data is captured using ThermoGenesis' proprietary DataTrak software to assist with Good Manufacturing Practice process monitoring and reporting information.
About Orthohealing Center Management, LLC.
Los Angeles-based Orthohealing Center is the premier destination for state-of-the-art, minimally invasive orthopaedics where an expert team determines optimal treatment plans for its patients integrating the latest in orthopaedic science and technology with minimal down time. The newly launched Orthohealing Method provides a blueprint of proprietary protocols, clinical support and data collection for physicians interested in integrating platelet-rich plasma, bone marrow concentrate, and Lipoaspirate cutting-edge orthopaedic therapies into clinical practice. Among its benefits, OHM offers physicians on-site training and certification with pioneering physicians and key opinion leaders, competitive group purchase pricing on equipment, and an orthobiologic patient registry to collect outcomes data for benchmarking, publication, and quality control. For more information, visit: www.orthohealingmethod.com
About ThermoGenesis Corp.
ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market.
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. is a market leader in cell processing technologies and autologous cell therapies for regenerative medicine. For more information, visit: www.cescatherapeutics.com
|
Company Contact: |
Investor Contact: |
|
Thermogenesis Corp |
Rx Communications Group, LLC |
|
Wendy Samford, [email protected] (916-858-5191) |
Paula Schwartz, [email protected] (917-322-2216) |
View original content:SOURCE Cesca Therapeutics
